Navigation Links
BiOptix to highlight new carbonic anhydrase data at IBC's Biopharmaceutical Development & Production Week

BOULDER, Colo. and HUNTINGTON BEACH, Calif., Feb. 27, 2013 /PRNewswire/ -- BiOptix is highlighting new and compelling small molecule kinetics data from the new BiOptix 404pi at the IBC Biopharmaceutical Development & Production Week to be held from February 25 – March 1 2013 in Huntington Beach, CA.  These new data sets continue to underscore the versatility of the BiOptix 404pi, an SPR instrument that is built for both protein-protein kinetics as well as protein-small molecule interactions.

"The carbonic anhydrase data from the BiOptix 404pi demonstrate the cornerstone of the BiOptix value proposition:  high sensitivity, low noise and an ability to evaluate small molecule models," noted Ken Wilczek , Vice President of Sales and Marketing for BiOptix.  "Carbonic anhydrase analysis is the gold standard for evaluating SPR instrumentation and the BiOptix 404pi produces excellent data.  BiOptix has designed and built—in the USA—a versatile SPR instrument that is available to the research community at a reasonable price."

Researchers are invited to learn more about the new BiOptix 404pi via the BiOptix Innovators Program—a unique to the industry "try before you buy" SPR instrumentation demo program.  Additional details can be found at:

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:

SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
2. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
5. Isis Reports Financial Results and Highlights for First Quarter 2012
6. Delcath Highlights First Quarter 2012 And Recent Accomplishments
7. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
8. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
9. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
10. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
11. MedVantx MedStart™ Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
Post Your Comments:
(Date:11/30/2015)...  Kevin Smith has been appointed Chief Commercial ... in wireless monitoring of vital signs.  As CCO ... Mr. Smith will be responsible for the development ... will also directly oversee partnering with US hospitals ... SensiumVitals, the first early warning detection device to ...
(Date:11/30/2015)... LAKE, N.J. and SAN DIEGO ... and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... has accepted for filing the New Drug Application (NDA) ... the extended release formulation will offer patients a chronic ... ® ) is currently approved as an ...
(Date:11/30/2015)... 30, 2015 iCAD, Inc. (Nasdaq: ... its latest solutions for advanced image analysis and ... at the Radiological Society of North American (RSNA) ... from November 29 to December 4, 2015. ... iReveal®, an automated breast density assessment solution, PowerLook® ...
Breaking Medicine Technology:
(Date:11/30/2015)... Chicago, Ill. (PRWEB) , ... November 30, 2015 ... ... and Decision Support Solutions, announced at the Radiology Society of North America (RSNA) ... bookings have seen over 60% growth from 2014. Throughout 2015, the company ...
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... , ... November 30, 2015 , ... The successful filing ... pharmaceutical company. Because it is so important to this key industry segment, Regis Technologies ... your IND Filing” on December 4th at 11am EST. , Federal law does not ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Laser Center is one of a select few plastic surgeons in the New ... fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat ...
(Date:11/30/2015)... CALIF. (PRWEB) , ... November ... ... ( ), a leading provider of enterprise Time and Attendance/Workforce Management ... status in the Microsoft Partner Program with competencies in the Application Development, ...
Breaking Medicine News(10 mins):